Wedgewood Partners BMY trades
David Rolfe
David Rolfe Bristol-Myers Squibb Company stake
total: 97
Trades details
- Total transactions:
- 14
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 9
- Held since:
- 2019 Q4
- Held for:
- 13 quarters
- Latest activity:
- 2023 Q1
According to 2026 Q2 report, David Rolfe doesn't hold any Bristol-Myers Squibb Company (BMY) shares. To date, the estimated cost basis is nearly $62.7 for "buy" trades and estimated average "sell" price is $61.92. Wedgewood Partners first purchased BMY in 2019 Q4, initially acquiring 391,442 shares. Since the initial investment in Bristol-Myers Squibb Company (BMY), Wedgewood Partners has made 13 more transactions.
When did David Rolfe sell Bristol-Myers Squibb Company (BMY)?
David Rolfe sold off the entire Bristol-Myers Squibb Company (BMY) position in 2023 Q1.
When did David Rolfe buy Bristol-Myers Squibb Company (BMY)?
David Rolfe first invested in Bristol-Myers Squibb Company (BMY) in 2019 Q4 at the reported quarter-end price of $64.19 per share.
What's the cost basis of Wedgewood Partners's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $62.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $62.70
- Weighted AVG sell price:
- $61.92
David Rolfe's historical trades in Bristol-Myers Squibb Company
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q1
|
0.00%
|
0
|
$71.86
|
|
-100% (-4,175)
|
-0.06%
|
|
2022 Q4
|
0.06%
|
4,175
|
$71.86
|
$300,000
|
-23.04% (-1,250)
|
-0.02%
|
|
2022 Q3
|
0.07%
|
5,425
|
$70.97
|
$385,000
|
-8.44% (-500)
|
-0.01%
|
|
2022 Q2
|
0.08%
|
5,925
|
$76.96
|
$456,000
|
-14.44% (-1,000)
|
-0.01%
|
|
2022 Q1
|
0.07%
|
6,925
|
$72.92
|
$505,000
|
+48.13% (+2,250)
|
+0.02%
|
|
2021 Q4
|
0.04%
|
4,675
|
$62.25
|
$291,000
|
-11.79% (-625)
|
-0.01%
|
|
2021 Q3
|
0.04%
|
5,300
|
$59.06
|
$313,000
|
-5.78% (-325)
|
-0%
|
|
2021 Q2
|
0.05%
|
5,625
|
$66.67
|
$375,000
|
-92.58% (-70,210)
|
-0.72%
|
|
2021 Q1
|
0.74%
|
75,835
|
$63.12
|
$4,787,000
|
-81.68% (-338,222)
|
-3.18%
|
|
2020 Q4
|
3.82%
|
$62.03
|
-5.75% (-25,262)
|
|||
|
2020 Q3
|
4.19%
|
$60.29
|
+17.53% (+65,538)
|
|||
|
2020 Q2
|
3.72%
|
$58.80
|
+44.22% (+114,601)
|
|||
|
2020 Q1
|
2.74%
|
$55.74
|
-33.79% (-132,262)
|
|||
|
2019 Q4
|
2.55%
|
$64.19
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.